Gavin C. Preston

Aberdeen, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma.

Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma.

Journal: British journal of haematology
Published: June 03, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica
Published: January 21, 2026

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: June 16, 2025

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Journal: The New England journal of medicine
Published: December 11, 2023

Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.

Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.

Journal: American journal of hematology
Published: August 18, 2023

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology
Published: January 16, 2023

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Journal: British journal of haematology
Published: December 21, 2022

Nodules, nodes and non-functioning macrophages: A risk with ibrutinib therapy.

Nodules, nodes and non-functioning macrophages: A risk with ibrutinib therapy.

Journal: The journal of the Royal College of Physicians of Edinburgh
Published: September 23, 2022

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.

Journal: Blood
Published: October 28, 2021

Multiple phases of human occupation in Southeast Arabia between 210,000 and 120,000 years ago.

Multiple phases of human occupation in Southeast Arabia between 210,000 and 120,000 years ago.

Journal: Scientific reports
Published: May 17, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026